ライフサイエンスコーパス: stimulating hormone

1 case-control pairs were assessed for thyroid-stimulating hormone.

2 administration of recombinant human thyroid-stimulating hormone.

3 tenedione, luteinizing hormone, and follicle-stimulating hormone.

4 slightly decreased concentration of thyroid-stimulating hormone.

5 ld prompt measurement of circulating thyroid-stimulating hormone.

6 ive effects of [Nle, D-Phe]-alpha-melanocyte-stimulating hormone.

7 and levels of C-reactive protein and thyroid-stimulating hormone.

8 agouti-related protein and alpha-melanocyte stimulating hormone.

9 proopiomelanocortin-derived alpha-melanocyte-stimulating hormone.

10 s of adrenocorticotropin or alpha-melanocyte-stimulating hormone.

11 ion with its natural ligand alpha-melanocyte-stimulating hormone.

12 o euthyroid participants (defined by thyroid-stimulating hormone 0.4-4.0 mIU/L).

13 124)I PET/CT after recombinant human thyroid-stimulating hormone (124)I PET/CT as implemented in this

14 tro and in vivo data of new alpha-melanocyte-stimulating hormone (alpha-MSH) analogues which are N-te

15 ted release of anorexigenic alpha-melanocyte stimulating hormone (alpha-MSH) and orexigenic Agouti-re

16 C4R responds to an agonist, alpha-melanocyte-stimulating hormone (alpha-MSH) and to an antagonist/inv

17 the neuroprotective peptide alpha-melanocyte stimulating hormone (alpha-MSH) attenuates GABAergic los

18 revealed that both NPY and alpha-melanocyte-stimulating hormone (alpha-MSH) inhibit and stimulate, r

19 alpha-melanocyte stimulating hormone (alpha-MSH) is a melanocortin signal

20 Alpha-melanocyte stimulating hormone (alpha-MSH) is an anorexigenic pepti

21 The neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) is an important regulato

22 te-suppressing neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) is reduced, yet the mRNA

23 ed at revealing the role of alpha-melanocyte-stimulating hormone (alpha-MSH) on basophil function.

24 ng the effects of intra-VTA alpha-melanocyte stimulating hormone (alpha-MSH) on feeding and food rewa

25 We report that melanocyte-stimulating hormone (alpha-MSH) or ACTH induce ATR-pS435

26 ed and X-Ala-Asp-conjugated alpha-melanocyte stimulating hormone (alpha-MSH) peptides.

27 abeled Arg-X-Asp-conjugated alpha-melanocyte stimulating hormone (alpha-MSH) peptides.

28 nd the POMC-derived peptide alpha-melanocyte-stimulating hormone (alpha-MSH) promote satiety.

29 n of MC1R in melanocytes by alpha-melanocyte-stimulating hormone (alpha-MSH) stimulates cAMP signalli

30 ypothalamus (PVN), to block alpha-melanocyte-stimulating hormone (alpha-MSH) type 3 and 4 receptors,

31 ing the alpha-melanocortin (alpha-melanocyte-stimulating hormone (alpha-MSH))-induced increase in the

32 ng release of products like alpha-melanocyte-stimulating hormone (alpha-MSH), neuropeptide Y (NPY), g

33 ts, melanotan-II (MT-II) or alpha-melanocyte stimulating hormone (alpha-MSH), were unilaterally micro

34 eceptor to bind its ligand, alpha-melanocyte-stimulating hormone (alpha-MSH).

35 and lesional skin levels of alpha-melanocyte-stimulating hormone (alpha-MSH).

36 ce of stimulation by the agonist, melanocyte-stimulating hormone (alpha-MSH).

37 euron-derived MC4R agonist, alpha-melanocyte stimulating hormone (alpha-MSH).

38 hypothalamic Pomc mRNA and alpha-melanocyte-stimulating hormone (alphaMSH) peptide levels were marke

39 e, densities of AgRP- and alpha-melanocortin stimulating hormone (alphaMSH)-immunoreactive fibers wer

40 cAMP levels in response to alpha-melanocyte-stimulating hormone, an MC4R agonist, by blocking ligand

41 An alpha-melanocyte-stimulating hormone analogue can reduce sunlight sensiti

42 e safety and efficacy of an alpha-melanocyte-stimulating hormone analogue, afamelanotide, to decrease

43 peptides alpha-, beta-, and gamma-melanocyte-stimulating hormone and ACTH are full agonists for all o

44 ing superovulation with recombinant follicle-stimulating hormone and administration of gonadotropin-r

45 n 3,5,3'-triiodothyronine (T(3)) and thyroid-stimulating hormone and an increase in reverse T(3).

46 opiomelanocortin-derived peptides melanocyte-stimulating hormone and corticotropin.

47 Furthermore, an increase in follicle-stimulating hormone and decreases in testosterone and th

48 Associations of thyroid-stimulating hormone and free thyroxine with the outcomes

49 upplementation on maternal or infant thyroid-stimulating hormone and free thyroxine.

50 We assessed the association of thyroid-stimulating hormone and FT4 with the risk of SCD by usin

51 was associated with decreased serum follicle-stimulating hormone and higher claudin-11 expression alo

52 ed mRNA expression of both pituitary thyroid-stimulating hormone and hypothalamic thyrotropin-releasi

53 e in detail effects on secretion of follicle-stimulating hormone and luteinising hormone.

54 ody mass index (P = .05), and lower follicle-stimulating hormone and luteinizing hormone (each P < .0

55 We measured follicle-stimulating hormone and luteinizing hormone and added in

56 Pituitary gonadotropins follicle-stimulating hormone and luteinizing hormone are heterodi

57 e further found that WNT5a prevents follicle-stimulating hormone and luteinizing protein from up-regu

58 stratification have emerged, such as thyroid stimulating hormone and molecular markers.

59 rs or aged <60 years if their serum follicle-stimulating hormone and oestradiol concentrations were w

60 crophages, we observed that alpha-melanocyte-stimulating hormone and selective MC1-R agonists similar

61 to spermatozoa, whereas recombinant follicle-stimulating hormone and steroid hormones are ineffective

62 COR1DeltaID, the abnormally elevated thyroid-stimulating hormone and TH levels found in Thrb(PV) mice

63 ell-permeable peptide, a hormone (melanocyte stimulating hormone), and a blood-clotting agent can be

64 assayed for thyroid autoantibodies, thyroid-stimulating hormone, and anti-FcepsilonRIalpha antibodie

65 rtisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and free thyroxine levels.

66 nth analysis evaluated E2, E1, E1S, follicle-stimulating hormone, and luteinizing hormone levels in a

67 analytes (prostate specific antigen, thyroid stimulating hormone, and luteinizing hormone) were print

68 th the anorexigenic peptide alpha-melanocyte-stimulating hormone, and the opioid peptide beta-endorph

69 rotein cholesterol, creatine kinase, thyroid-stimulating hormones, and erythrocyte sedimentation rate

70 Follicle-stimulating hormone, anti-Mullerian hormone, and inhibin

71 ocedures for serum concentrations of thyroid-stimulating hormone are likewise under development.

72 y of the endogenous agonist alpha-melanocyte-stimulating hormone at the MC4R by 37- and 600-fold, res

73 the density of anorexigenic alpha-melanocyte-stimulating hormone axons was reduced in adult Magel2-nu

74 P, rs11031006, in the region of the follicle-stimulating hormone B polypeptide (FSHB) gene strongly a

75 We found that thyroid-stimulating hormone beta subunit (tshb) and type 2 deiod

76 from the hypothalamus and regulates follicle-stimulating hormone beta-subunit (FSHbeta) gene expressi

77 0.092, -0.013), and increasing log10 thyroid-stimulating hormone (beta = 0.071; 95% CI: 0.008, 0.133)

78 Increased levels of follicle-stimulating hormone (beta = 0.20, 95% confidence interva

79 g levels of luteinizing hormone and follicle-stimulating hormone but apparently normal responsiveness

80 liver, and renal function; and serum thyroid-stimulating hormone concentration lower than 0.5 mIU/L.

81 menses or since hysterectomy with a follicle-stimulating hormone concentration of >=40 U/L) with oste

82 iables: age, body-mass index, basal follicle-stimulating hormone concentration, and the number of pre

83 ons are based on the degree to which thyroid-stimulating hormone concentrations have deviated from no

84 (TT(4)), total triiodothyronine, and thyroid-stimulating hormone concentrations were compared with FR

85 he endogenous MC4R agonist alpha-melanoctyte-stimulating hormone course parallel and wrap around ante

86 ifferent molecular sizes, [d-Trp]-melanocyte-stimulating hormone, [d-Ala]-deltorphin, [d-Phe]-achatin

87 (12.5%), precocious puberty (12.2%), thyroid-stimulating hormone deficiency (9.2%), and thyroidal hyp

88 ce, but it does not restore alpha-melanocyte-stimulating hormone-dependent cAMP signaling.

89 eled lactam bridge-cyclized alpha-melanocyte stimulating hormone derivative, betaAlaNleCycMSH(hex).

90 or persistently reduced secretion of thyroid-stimulating hormone despite low plasma thyroid hormone.

91 unclear which individuals with mild thyroid-stimulating hormone elevations will benefit from levothy

92 nduced thyrotropin-releasing hormone/thyroid-stimulating hormone expression.

93 Thyroid stimulating hormone, free thyroxine, 25-hydroxy vitamin

94 n erythropoietin (hEPO) is an erythropoiesis stimulating hormone frequently employed in antianemia th

95 n hormones (luteinizing hormone and follicle-stimulating hormone) from the pituitary.

96 Follicle stimulating hormone (FSH) acts through receptors (FSHR)

97 t of male infertility is the use of follicle stimulating hormone (FSH) analogs which improved sperm n

98 Serum follicle-stimulating hormone (FSH) and E2 were measured at baseli

99 of menses and serial monitoring of follicle-stimulating hormone (FSH) and inhibin A and B levels.

100 Although both the levels of follicle-stimulating hormone (FSH) and inhibin B are correlated w

101 productive physiology by regulating follicle-stimulating hormone (FSH) and luteinizing hormone (LH) g

102 itor of prostaglandin signaling and follicle-stimulating hormone (FSH) and luteinizing hormone (LH) s

103 ulates the pituitary gonadotropin's follicle-stimulating hormone (FSH) and luteinizing hormone (LH),

104 osterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and sex hormone-binding globul

105 Follicle-stimulating hormone (FSH) and syt-9 are highly co-locali

106 , we briefly outline the roles that follicle-stimulating hormone (FSH) and testosterone play in regul

107 y-mass index of 19-35 kg/m(2) and a follicle-stimulating hormone (FSH) concentration of 3.0-20.0 mIU/

108 he preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range.

109 ta-subunit of the pituitary hormone follicle-stimulating hormone (Fsh) increases bone mass in mice.

110 Follicle-stimulating hormone (FSH) is an essential regulator of g

111 st whether treatment with exogenous follicle-stimulating hormone (FSH) is capable of rescuing phenoty

112 d on evidence that the GPCR agonist follicle-stimulating hormone (FSH) promotes the protein kinase A

113 Follitropin, or follicle-stimulating hormone (FSH) receptor (FSHR), is a G protei

114 of transcription, androgens enhance follicle-stimulating hormone (FSH) receptor expression, which the

115 Follicle-stimulating hormone (FSH) regulates follicular growth an

116 vation of protein kinase A (PKA) by follicle stimulating hormone (FSH) transduces the signal that dri

117 vel of antimullerian hormone (AMH), follicle-stimulating hormone (FSH), and inhibin B and urinary lev

118 Estrogen, follicular stimulating hormone (FSH), and luteinizing hormone (LH)

119 Estrogen (E2), follicular stimulating hormone (FSH), and luteinizing hormone (LH)

120 the synthesis of the gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH).

121 sures of ovarian reserve were day-3 follicle-stimulating hormone (FSH), antral follicle count (AFC),

122 s innervation was observed close to follicle-stimulating hormone (FSH), luteinizing hormone (LH) and

123 perm count and concentration, serum follicle stimulating hormone (FSH), luteinizing hormone (LH) and

124 (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, fasting plasma glu

125 lation, and thus, the expression of follicle-stimulating hormone (FSH)- and testosterone-induced targ

126 ian cancer nor its interaction with follicle-stimulating hormone (FSH)-driven proliferation in ovaria

127 essing luteinizing hormone (LH) and follicle-stimulating hormone (FSH)], with adrenocorticomelanotrop

128 emature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] >/= 40 IU/L) after 1 year of f

129 The beta subunit of follicle stimulating hormone (FSHB) is expressed specifically in

130 am Study with data available on TSH (thyroid-stimulating hormone), FT4 (free thyroxine) and gait, wit

131 Reductions in levels of the hunger-stimulating hormone ghrelin have been proposed to mediat

132 refore investigated the role of the appetite-stimulating hormone ghrelin in olfactory processing in r

133 ression driving the production of the growth-stimulating hormone gibberellic acid and downstream grow

134 based on baseline blood sampling for thyroid stimulating hormone, gonadotropin, and prolactin deficie

135 Thyroid stimulating hormone (h(2)=0.58, P=2 x 10(-)(5)) and immu

136 gamma-MSH (gamma-melanocyte-stimulating hormone, H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-A

137 -density lipoprotein, triglycerides, thyroid stimulating hormone, homocysteine, C-reactive protein an

138 f experiments (DOE) optimization for thyroid-stimulating hormone immunoassays, varying (1) the analyt

139 iffer among the four groups, whereas thyroid-stimulating hormone increased upon iodine supplementatio

140 n of STRN and to a kinase-dependent, thyroid-stimulating hormone-independent proliferation of thyroid

141 In cultured hypothalamic neurons, melanocyte stimulating hormone induces an MC4R-dependent and sustai

142 ortin (POMC) that is processed to melanocyte-stimulating hormone, inducing tanning.

143 We have previously shown that thyroid-stimulating hormone is required, but not sufficient to i

144 amelanotide, an analogue of alpha-melanocyte-stimulating hormone, is known to induce tanning of the s

145 nd testicular weight, testosterone, follicle-stimulating hormone level, and luteinizing hormone level

146 Hematocrit level, thyroid stimulating hormone level, autoimmune antibody level, er

147 ely 50-80%) and profoundly increased thyroid-stimulating hormone levels ( approximately 800-1000-fold

148 al, 1.68-3.47 per 1 ng/dL) and lower thyroid-stimulating hormone levels (hazard ratio, 0.92; confiden

149 netically predicted 1 SD decrease in thyroid-stimulating hormone levels and 1.05 (95% CI, 1.03-1.08;

150 Genetically predicted thyroid-stimulating hormone levels and hyperthyroidism were stat

151 ) mice exhibit highly elevated serum thyroid-stimulating hormone levels and increased TH.

152 or a causal association of decreased thyroid-stimulating hormone levels in the direction of a mild fo

153 subclinical hypothyroidism (based on thyroid-stimulating hormone levels of 4.1 to 11.0 mIU/L), 1 fair

154 ical thyroid dysfunction, defined as thyroid-stimulating hormone levels outside the reference range w

155 vier menstrual bleeding, and higher follicle-stimulating hormone levels were associated with longer m

156 and tandem mass spectrometry assay; follicle-stimulating hormone levels were measured at baseline and

157 Serum-luteinizing and follicle-stimulating hormone levels were normal, with a borderlin

158 t in GNAS associating with increased thyroid-stimulating hormone levels when maternally inherited.

159 ll count, C-reactive protein levels, thyroid-stimulating hormone levels, and thyroid peroxidase antib

160 yroxinemia without markedly lowering thyroid stimulating hormone levels, thus creating a biochemical

161 ed using anti-Mullerian hormone and follicle-stimulating hormone levels, was similar in both groups.

162 TNs are seen in patients with normal thyroid-stimulating hormone levels.

163 ings (insulin-like growth factor 1, follicle-stimulating hormone, luteinizing hormone, and testostero

164 ther by the agonistic MC1R ligand melanocyte stimulating hormone (MSH) or by pharmacologic cAMP induc

165 C) receptor agonist DTrp(8)-gamma-melanocyte stimulating hormone (MSH; DTrp).

166 such as alpha-, beta-, and gamma2-melanocyte stimulating hormones (MSH) and adrenocorticotropin hormo

167 protein (AGRP)/[Nle4,DPhe7]alpha-melanocyte stimulating hormone (NDP-MSH) ligands is reported.

168 ffect of [Nle(4), D-Phe(7)]-alpha-melanocyte stimulating hormone (NDP-MSH), a potent non-steroidogeni

169 the bound ligand [Nle(4),D-Phe(7)]melanocyte-stimulating hormone (NDP-MSH), thereby differentiating b

170 de glutamic acid-isoleucine/alpha-melanocyte-stimulating hormone (NEI/alphaMSH) peptides.

171 he FMP in the log rate of change of follicle-stimulating hormone (odds ratio, 0.65; 95% CI, 0.46-0.91

172 the Rotterdam Study >/=45 years with thyroid-stimulating hormone or free thyroxine (FT4) measurements

173 o changes in serum concentrations of thyroid-stimulating hormone or free tri-iodothyronine, free tetr

174 ompetitively inhibits the binding of thyroid-stimulating hormone or the human autoantibody to TSHR.

175 um thyrotropin (often referred to as thyroid-stimulating hormone, or TSH) level with normal levels of

176 ft ventricular dysfunction, elevated thyroid stimulating hormone, palmar-plantar erythrodysesthesia,

177 eled lactam bridge-cyclized alpha-melanocyte-stimulating hormone peptides.

178 ease compared to KP10 and increased follicle-stimulating hormone plasma concentration.

179 pared from 7B2 null mice restored melanocyte-stimulating hormone production, substantiating the role

180 eatment with R-spondin2, similar to follicle stimulating hormone, promoted the development of primary

181 stimulation with the letrozole and follicle-stimulating hormone protocol preserves fertility in wome

182 tact parathyroid hormone (iPTH), and thyroid stimulating hormone; psychological symptom inventories (

183 Follicle-stimulating hormone receptor (FSHR), a G-protein coupled

184 in a classical pigmentation gene, melanocyte stimulating hormone receptor (MC1R), is strongly associa

185 of stimulating autoantibodies to the thyroid-stimulating hormone receptor (TSHR) (TSAbs) that induce

186 Tg and the thyroid-stimulating hormone receptor (TSHR) are targets for auto

187 Genetic associations of the thyroid stimulating hormone receptor (TSHR) gene with GD and GO

188 5 and rs12101261) in intron 1 of the thyroid stimulating hormone receptor (TSHR) gene.

189 The thyroid stimulating hormone receptor (TSHR) is a G protein-coupl

190 come is predicted for over a hundred thyroid stimulating hormone receptor (TSHR) mutations, as well a

191 e of autoantibodies that bind to the thyroid-stimulating hormone receptor (TSHR) on the thyroid gland

192 m is caused by autoantibodies to the thyroid-stimulating hormone receptor (TSHR) that act as agonists

193 teinizing hormone receptor (LHR) and thyroid-stimulating hormone receptor (TSHR)) was expected to be

194 luteinizing hormone receptor and the thyroid-stimulating hormone receptor (TSHR), stimulation with a

195 The genes for thyroid-stimulating hormone receptor (TSHR), the SOX11 transcrip

196 dide symporter, thyroperoxidase, and thyroid-stimulating hormone receptor and to a moderate accumulat

197 and coordinating the expression of a thyroid-stimulating hormone receptor antagonist (TSHAntag), whic

198 thyroperoxidase or thyroglobulin, or thyroid-stimulating hormone receptor antibodies (TRAbs), or a co

199 agonist and antagonist activities of thyroid-stimulating hormone receptor autoantibodies.

200 in p10 can inhibit activation of the thyroid-stimulating hormone receptor by autoantibodies.

201 ons that were created by joining the thyroid stimulating hormone receptor exoloops constrained throug

202 with human brittle bone disease and thyroid stimulating hormone receptor hyperactivity.

203 ollicle stimulating hormone receptor/thyroid stimulating hormone receptor were mapped using exoloop-s

204 ferentiation markers, thyroglobulin, thyroid-stimulating hormone receptor, thyroid peroxidase, and so

205 ked to photoperiod and reproduction (thyroid-stimulating hormone receptor, TSHR).

206 ssion and showed decreased levels of thyroid stimulating hormone receptor-stimulating Abs and frequen

207 melanoma through targeting of the melanocyte-stimulating hormone receptor.

208 ops of luteinizing hormone receptor/follicle stimulating hormone receptor/thyroid stimulating hormone

209 but in states of hyperactivation of thyroid-stimulating hormone receptors (TSHRs), patients develop

210 ases beta-endorphin but not alpha-melanocyte-stimulating hormone release in the hypothalamus, and sys

211 before light onset, whereas alpha-melanocyte stimulating hormone release, especially at the end of th

212 primary follicles elicits defective follicle-stimulating hormone responsiveness blocking development

213 receptor binding with the agonist melanocyte-stimulating hormone resulted in an increased proportion

214 with injections of recombinant human thyroid-stimulating hormone (rhTSH) and thyroid hormone withdraw

215 section and use of recombinant human thyroid stimulating hormone (rhTSH) for (1)(3)(1)I radioactive i

216 ithdrawal (THW) or recombinant human thyroid-stimulating hormone (rhTSH) injections before (131)I adm

217 epared with either recombinant human thyroid-stimulating hormone (rhTSH) or thyroid hormone withdrawa

218 administration of recombinant human thyroid-stimulating hormone (rhTSH).

219 was cost-effective as compared with thyroid-stimulating hormone screening.

220 weight loss by reducing ghrelin, an appetite-stimulating hormone secreted from the gastric fundus.

221 Hyperthyroidism due to thyroid-stimulating hormone-secreting tumors accounts for 1% of

222 sed luteinizing hormone relative to follicle-stimulating hormone secretion, insulin resistance and de

223 ocortin analog [Nle, D-Phe]-alpha-melanocyte-stimulating hormone (starting 3 or 6 hrs after injury) i

224 ough follicles responded to initial follicle-stimulating hormone stimulation and developed normally u

225 support the use of urinary or blood follicle-stimulating hormone tests or antimullerian hormone level

226 ulation of melanogenesis by alpha-melanocyte-stimulating hormone through melanocortin 1 receptor.

227 arkers of thyroid function including thyroid-stimulating hormone, thyroglobulin, total and free thyro

228 othyronine (T3) and thyroxine (T4)), thyroid-stimulating hormone, thyroid peroxidase antibodies, iodi

229 Ratios of follicle stimulating hormone to luteinizing hormone, a sexual mat

230 11 analytes included 9 hormones (ie, thyroid-stimulating hormone, total thyroxine, total triiodothyro

231 The euthyroid state was defined as thyroid-stimulating hormone (TSH) 0.45 to 4.49 mIU/L, and subcli

232 and competitive immunoassays, using thyroid stimulating hormone (TSH) and 17beta-estradiol (E2) as m

233 ek specific associations of maternal thyroid-stimulating hormone (TSH) and free thyroxine (fT4) level

234 axis maintains circulating levels of thyroid stimulating hormone (TSH) and thyroid hormone (TH) in an

235 strate that GLIS3 acts downstream of thyroid-stimulating hormone (TSH) and TSH receptor (TSHR) and is

236 Neither catecholamines nor thyroid-stimulating hormone (TSH) are responsible for sarcolipin

237 y >3% of the population with newborn thyroid-stimulating hormone (TSH) concentration >5 mIU/L, median

238 m, and is usually defined as a serum thyroid-stimulating hormone (TSH) concentration greater than the

239 Since thyroid-stimulating hormone (TSH) exerts an inductor effect on c

240 fication of pCB films with antihuman thyroid stimulating hormone (TSH) IgG molecules and the detectio

241 enocorticotropic hormone (ACTH), and thyroid stimulating hormone (TSH) in both normal and tumor tissu

242 he mediobasal hypothalamus (MBH) and thyroid-stimulating hormone (TSH) in the pituitary.

243 d free thyroxine (T4), total T4, and thyroid-stimulating hormone (TSH) in women during pregnancy, and

244 Thyroid stimulating hormone (TSH) is critical for normal develop

245 Semi-quantitative thyr oid stimulating hormone (TSH) lateral flow immunochromatogra

246 SCH was defined as a serum thyroid-stimulating hormone (TSH) level of 5.0 to 19.96 mIU/l wi

247 ata showing correlations between low thyroid-stimulating hormone (TSH) levels and high bone turnover

248 that exerts the hormonal control of thyroid-stimulating hormone (TSH) levels as well as neuromodulat

249 rmone levels, and none have measured thyroid-stimulating hormone (TSH) levels in neonates.

250 by low thyroid hormone (TH) and high thyroid-stimulating hormone (TSH) levels in the serum, is strong

251 positively associated with maternal thyroid-stimulating hormone (TSH) levels.

252 zed by high thyroid hormone (TH) and thyroid-stimulating hormone (TSH) levels.

253 Serum thyroid-stimulating hormone (TSH) measurement is the best diagno

254 ations for the functional reserve of thyroid-stimulating hormone (TSH) production and the TSH set poi

255 ice: 1) The development of the serum thyroid-stimulating hormone (TSH) radioimmunoassay led to the di

256 The thyroid-stimulating hormone (TSH) receptor signals via G(s) to p

257 caused by autoantibodies against the thyroid-stimulating hormone (TSH) receptor.

258 g TH levels are tightly regulated by thyroid-stimulating hormone (TSH) secretion within the hypothala

259 tion rate was equivalent for the two thyroid-stimulating hormone (TSH) stimulation methods (thyroid h

260 hs; necropsy was performed and serum thyroid stimulating hormone (TSH) was measured.

261 nine (fT3), free thyroxine (fT4) and thyroid stimulating hormone (TSH) was measured.

262 rease in the pituitary expression of thyroid-stimulating hormone (TSH), an increase in the blood conc

263 Plasma free T4, thyroid-stimulating hormone (TSH), and 8 am cortisol levels were

264 ditis (AIT), serum concentrations of thyroid-stimulating hormone (TSH), and autoantibodies to thyrope

265 erum levels of free thyroxine (FT4), thyroid-stimulating hormone (TSH), and thyroid peroxidase antibo

266 that the anterior pituitary hormone, thyroid-stimulating hormone (TSH), can bypass the thyroid to exe

267 and biomarkers of thyroid function [thyroid-stimulating hormone (TSH), free and total thyroxine (fT4

268 e changes in concentrations of serum thyroid-stimulating hormone (TSH), free and total thyroxine (T(4

269 s according to genetically predicted thyroid stimulating hormone (TSH), free thyroxine (FT4) and thyr

270 s, including serum concentrations of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thy

271 total testosterone, prolactin (PRL), thyroid stimulating hormone (TSH), free triiodothyronine (fT3),

272 Serum levels of thyroid-stimulating hormone (TSH), total thyroxine (TT4), and PF

273 t depends on tanycyte sensitivity to thyroid stimulating hormone (TSH), which is dramatically and per

274 There is evidence, however, that thyroid-stimulating hormone (TSH), which is low in most hyperthy

275 pharmaceuticals, negatively regulate thyroid-stimulating hormone (TSH)-dependent Ca(2+) increases and

276 Thyroid-stimulating hormone (TSH)-induced reduction in ligand bi

277 an 1, 1998, and Dec 31, 2013, from a thyroid-stimulating hormone (TSH)-receptor antibody (TRAb) test

278 Depletion of LXRs activated thyroid-stimulating hormone (TSH)-releasing hormone (TRH)-positi

279 TC rapidly with high levels of serum thyroid-stimulating hormone (TSH).

280 l triiodothyronine (T3), free T4, or thyroid-stimulating hormone (TSH).

281 4) along with normalization of serum thyroid-stimulating hormone (TSH).

282 expression increases in response to thyroid-stimulating hormone (TSH).

283 peroxidase antibody (Anti-TPO), and thyroid stimulating hormone (TSH).

284 etween anti-Dechlorane Plus (DP) and thyroid-stimulating hormone (TSH).

285 The thyrotropin [thyroid-stimulating hormone (TSH)] receptor (TSHR) is known to a

286 ity and explore the relation between thyroid-stimulating hormone (TSH; also known as thyrotropin) lev

287 free triiodothyronine [TT3 and FT3], thyroid-stimulating hormone [TSH], and thyroglobulin [Tg]) and l

288 nt was POF, defined as at least one follicle-stimulating hormone value of > 40 IU/L after 2 years of

289 ine aminotransferase (p = 0.035) and thyroid-stimulating hormone values (p = 0.013) than those with n

290 only a small number of patients with thyroid-stimulating hormone values of more than 10 mIU/L have be

291 78, 95% CI 2.00-16.67; p=0.001), and thyroid stimulating hormone was increased on average by 4.00 iU/

292 At the last follow-up visit, thyroid-stimulating hormone was similar in both groups.

293 thyroxine </=10th percentile, normal thyroid-stimulating hormone) was associated with an increased od

294 e aromatase and the receptor of the follicle stimulating hormone were higher in contaminated fish tha

295 hyroxine, free triiodothyronine, and thyroid-stimulating hormone were measured in 1996 (n = 909) and

296 gesterone, luteinizing hormone, and follicle-stimulating hormone were measured in serum up to 8 times

297 gesterone, luteinizing hormone, and follicle-stimulating hormone were measured up to 8 times per cycl

298 one (GnRH) agonists and recombinant follicle-stimulating hormone were studied prospectively.

299 maintain high urine output; alpha-melanocyte-stimulating hormone, with anti-inflammatory and antiapop

300 r (DTC) may be prepared using either thyroid-stimulating hormone withdrawal (THW) or recombinant huma